

## CASE STUDY

# A Case Report on Management of Non-alcoholic Grade 2 Fatty Liver WSR *Yakrit Vikara* through Ayurvedic Intervention

Durgesh Kumar<sup>1\*</sup>, Atal Bihari Trivedi<sup>2</sup>, S.S. Mohan Kumar<sup>1</sup>

<sup>1</sup>PG Scholar, Department of Kayachikitsa, Ch. Brahm Prakash Ayurved Charak Sansthan, New Delhi, India.

<sup>2</sup>Associate Professor, Department of Kayachikitsa, Ch. Brahm Prakash Ayurved Charak Sansthan, New Delhi, India.

### ARTICLE INFO

#### Article history:

Received on: 21-04-2025

Accepted on: 13-05-2025

Published on: 31-05-2025

#### Key words:

*Arogyavaradhini Vati,*  
*Ayurveda,*  
*Capsule Kalamegha,*  
*Makoi Arka,*  
*Medohara Guggulu,*  
*Purnanava mandoor,*  
*Yakrit Vikara*

### ABSTRACT

One of the most prevalent liver conditions in the world, fatty liver, is typically brought on by lipid build-up, primarily triglycerides in hepatocytes. Although the liver naturally contains fat, fatty liver can develop if the amount of fat exceeds 5–10% of the liver's total weight. *Yakrit* (liver) is considered as a crucial organ responsible for digestion, metabolism, detoxification in body. In *Ayurveda* non-alcoholic grade 2 fatty liver disease can be related with *Yakrit Vikara* primarily caused by imbalance of *Pitta Dosha* leading to conditions such as jaundice, fatty liver, liver cirrhosis and hepatitis etc. this case study examines the clinical presentation, diagnosis and treatment of a male patient aged 60 years with complaint of gaseous abdomen, increased body weight, pain in right side of abdomen, and incomplete bowel evacuation since last 2 months. Diagnostic ultrasound report confirmed grade 2 fatty liver in both lobes. He was managed with oral medications including *Purnanava Mandoor* two tablets twice a day, *Arogyavaradhini Vati* two tablets twice a day, *Capsule Kalamegha* one tablet twice a day, *Medohara Guggulu* two tablets twice a day, *Makoi Arka* 10 mL once daily (Empty stomach). This case underscores the potential of *Ayurveda* in managing Grade 2 fatty liver disease by addressing the root cause of the condition and promoting holistic healing approach.

## 1. INTRODUCTION

In *Ayurveda*, the phrase “*Yakrut Dalyodara*” refers to the expansion of the liver (*Yakrit Vridhi*). When the size of the liver increases due to the rise in the *Kapha Dosha* then it called as *Kaphja Yakrit Dalyodara*. Then the *Meda* is increased inside the liver and results in the formation of *Medaja Yakrit Dalyodara*. In *Bhavprakash Samhita*, *Acharya Bhavmishra* is the first *Acharya* which describe the term *Yakrit Vikar* with its classification and *Chikitsa*.<sup>[1]</sup> It describes *Yakrit Vikar* are of four types *Vataj*, *Pittaj*, *Kaphaj*, *Raktaj*. *Vataj Yakrit Vikara* has symptoms of *Nitya Mandaddha Bkosta*, *Nityadarvarta Peedita*: *Pitta* has features of *Jwar*, *Pipasa*, *Daha*: *Kaphaj* have lakshan of *Manda Vyatha*, *Shola*, *Kathina*, *Gaurava*, and *Raktaj* have *Klama*, *Bhrama*, *Vidaha*, *Vaivarnya*, *Gatra Gaurava*.<sup>[2]</sup> The incomplete description of *Nidan*, *Poorvaroopa*, *Rupa Lakshan Chikitsa* of *Yakrit Vikar* is also available in *Charak Samhita*, *Susrut Samhita*, *Ashtang Hridaya* And *Madhav Nidana*. According to *Acharya Sushruta*, ten *Raktavaha Sira* are connected to *Yakrit* and *Pleeha*.<sup>[3]</sup> *Sushruta* also noted that

*Raktadhara Kala* is especially found in *Sira*, *Yakrit*, And *Pleeha*. *Yakrit* is site for *Ranjak Pitta*. After absorption, *Rasa Dhatu* goes to the metabolism with the help of *Agni* and *Ranjak Pitta*, some part of this *Rasa Dhatu* converts into *Rakta Dhatu*. *Yakrit* mainly functions upon the nourishment of *Rakta*.

Like *Sthaulya*, fatty liver disease is a *Santarpanajanya Vyadhi* (overeating disease) with *Samprapti* (pathogenesis) and *Nidana* (aetiology). The vitiation of *Kaphadosha* and the uneven formation and deposit of *Meda* (fat tissue) in *Yakrit* are caused by *Agnivikruti* (Vitiation of the Digestive System), which results in the production of *Apakva Anna Rasa* (Improperly formed digestive end product). The medical term for this condition is fatty liver. Vitiated *Kapha* and *Meda* generate *Srotorodha* (channel obstruction), which in turn encourages *Vata*. The cycle repeats when vitiated *Vata* leads to *Agnivikruti*. When *Pitta* is linked to the pathophysiology, hepatocytes experience inflammatory changes, and the disease progresses to the next stage, non-alcoholic steatohepatitis (NASH). Fibrosis arises when *Vata* enters the equation, and the illness may worsen to its most severe stages. When *Pitta* is involved in the pathophysiology, hepatocytes undergo inflammatory changes, and the disease progresses to the next phase. Fibrosis, which arises when *Vata* enters the equation, can result

#### Corresponding Author:

Durgesh Kumar,  
PG Scholar, Department of Kayachikitsa, Ch. Brahm  
Prakash Ayurved Charak Sansthan, New Delhi, India.  
Email: [jangradurgesh007@gmail.com](mailto:jangradurgesh007@gmail.com)

in cirrhosis, ascites, hepatocellular cancer, and other metabolic issues. Key factors in the etiopathogenesis of fatty liver include vitiation of *Samanavayu*, *Apanavayu*, *Pachakapitta*, *Ranjakapitta*, *Kledaka kapha*, *Rasa Rakta Medo dhatu*, and *Pureesha*.<sup>[4]</sup> The *Srotas Annava*, *Udakavaha*, *Rasavaha*, *Raktavaha*, *Medovaha*, and *Pureeshavaha* are linked to the aetiology and manifestation of fatty liver disorder.

Non-alcoholic fatty liver disease (NAFLD), is made up of two conditions: non-alcoholic fatty liver and NASH. Steatosis is the build-up of fat in the liver, while steatohepatitis is an inflammatory condition. NAFLD is a growing epidemic worldwide due to unhealthy lifestyle and obesity, with a prevalence rate in the population ranging from 11.2% to 37.2%. In India, it has been rapidly rising in very recent years with the prevalence of NAFLD varying from 8% to 35%. With a higher frequency among individuals who are obese and overweight, and those who are diabetic or pre-diabetic.

NAFLD is a benign type of disease where deposition of fat occurs (steatosis) in >5% of the hepatocytes histologically.<sup>[5]</sup> Lifestyle changes, increased fatty cell deposition, insulin resistance are the major factors for this disease. In the absence of excessive alcohol intake, NAFLD ranges from simple steatosis to non-alcoholic steatosis with or without cirrhosis.<sup>[6]</sup>

## 2. CASE REPORT

A 60-year-old non-alcoholic, married male patient, relatively obese (body mass index = 30.2) from an urban area, came for Ayurveda treatment in Ayurvedic practitioner's outpatient department at Ch. Brahm Prakash Ayurved Charak Sansthan Khera Dabar, Najafgarh. The patient was coming with the complaint of gaseous abdomen, weight gain, and loss of appetite. These symptoms have been persisting in the patient for the past 6 months.

### 2.1. Case Findings

The patient's pulse rate was 80/min, blood pressure was 140/84 mm of Hg, and respiratory rate was 16/min. The body temperature was 98.7 F. No abnormal clinical findings found at the time of examination in cardiovascular and respiratory examination. His abdomen was distended and tympanic due to a gaseous abdomen. On palpitation, tenderness was found in the right upper quadrant and the umbilical region. During the percussion dull sound was found in the right upper quadrant, and bowel sound was increased and normal. No past history of any surgical intervention and psychological illness. No family history of any genetic disorder.

Dashvidha Pariksha (tenfold examination of the patient) was done for patient assessment. The patient has: Vata-Kaphaja in Prakriti, Vikriti Pitta - Kaphaja, Vishama Pramana (anthropometry), Madhyama Sara, Madhyam Satva, Madhyam Satmya, Avara Aahar Shakti, Madhyam Vaya, Avara Vyayam Shakti, and Avara Bala (strength).

### 2.2. Assessment Criteria

The patient was already diagnosed with grade 2 fatty liver in both lobes. The diagnosis with Ayurveda perspective was *Yakrit Dalyodara* (liver disease) associated with *Medodushti* (obesity). Liver measures 12.9 cm in craniocaudal span, and both lobes show grade 2 fatty liver with normal sized biliary and vascular channel. There was no sign of fluid accumulation, abnormal increase in temperature.

### 2.3. Therapeutic Intervention

Therapeutic intervention is mentioned in table 1.

### 2.4. Timelines

Timelines are mentioned in table 2.

### 2.5. Pathya-Apathya

Patient was advised to follow below *Pathya-Apathya*<sup>[7,8]</sup> diet regimen in Table 4:

## 3. RESULTS

The outcome was evaluated based on improvements in the patient's overall health, including weight gain, loss of appetite, gaseous abdomen, and heaviness in the abdomen. Also change in the ultrasonographic image from grade 2 fatty liver to mild fatty infiltration [Table 3].

## 4. DISCUSSION

The presented patient is *Kapha Pittaj* in *Prakriti*, and other parameters shown *Kapha* predominant. Therefore, in Ayurvedic texts patients' symptoms were matched with *Yakrit Dalyodara* for NAFLD. The above-mentioned drugs are *Tikta* in nature that provides relief by its *Srotas Shodhak* properties (micro channel cleaning). This case study proves that in above treatment plan can significantly improve the symptoms of disease as well as changes in the ultrasound reports from grade 2 fatty liver to mild fatty infiltration. Above treatment may correct the metabolic dysfunction by increasing *Agni* and digesting the *Ama*. There were no adverse signs and symptoms observed in patients by above treatment. The patient was kept in observation for 3 months without medications and advised to do exercise, and low saturated fat and deep-fried items with low carbohydrate diet to prevent from recurrence of disease.

### 4.1. Probable Mode of Action of *Arogyavardhini vati*

*Arogyavardhini*<sup>[9]</sup> *Vati* balances the three *Doshas*, which enhances general health. The medication has no discernible toxicological effects on the kidney, liver, or brain. This treatment is often referred to as fatty liver remedies and natural liver cleansing. It maintains a healthy digestive system, encourages equilibrium, and supports liver function. The *Shoshan* (assimilation) of various surplus *Snigdha Dravyas* (unctuous substances) in the body is performed by *Arogyavardhini vati*. In addition, it performs the *Raktavardhana* (blood purification) and the *Pachan* (digestion) of *Drava* (liquid) and *Kleda* (clammy). It lowers *Snigdhatva* and *Dravatva* in *Meda Dhatu*. To get the intended effect, the medication must be taken with a variety of adjuvants. To prevent any negative effects, self-medication of the drug should be rigorously avoided. *Haritaki* (*Terminalia chebula*), an astringent and laxative, is one of the drug's components. It is helpful in treating fatty liver and liver cirrhosis and is efficient in treating liver problems. The herb *Bibhitaki* (*Terminalia belerica*) is an excellent anthelmintic, a laxative, and a useful treatment for digestive issues. Because of its styptic properties, it can be used to stop bleeding. *Amalaki* (*Emblica officinalis*), another component, has antibacterial, carminative, hypoglycemic, stomachic, hypotensive, and astringent properties. It has immune-modulating, antioxidative, and anti-hepatotoxic qualities. One useful substance for reviving vigor is the mineral *Shuddh Shilajit*. It contains strong antioxidant qualities and functions similarly to nectar, delaying the aging process. It helps with mental illness, liver disease, kidney disease, and digestive issues. *Guggulu* (*Commiphora mukul*), an oleo-gum-resin, aids in the elimination of cholesterol by turning it into bile. It is a useful treatment for regulating cholesterol levels and eliminating excess fat. *Chitrak* (*Plumbago zeylanica*) is a herb that effectively treats a variety of liver problems, worms, piles,

indigestion, loss of appetite, and colitis. *Picrorrhiza kurroa*, another crucial component, is a potent treatment for liver conditions. It works well for liver damage brought on by substances like alcohol, paracetamol, and carbon tetrachloride.

(Commiphora mukul), an oleo-gum-resin, aids in the elimination of cholesterol by turning it into bile. It is a useful treatment for regulating cholesterol levels and eliminating excess fat. *Chitrak* (*Plumbago zeylanica*) is an herb that effectively treats a variety of liver problems, worms, piles, indigestion, loss of appetite, and colitis. *Picrorrhiza kurroa*, another crucial component, is a potent treatment for liver conditions. It works well for liver damage brought on by substances like alcohol, paracetamol, and carbon tetrachloride.

#### 4.2. Probable Mode of Action of *Punarnava Mandura*

*Punarnava Mandura* provided a significant improvement on all subjective parameters of *Garbhini Pandu*, due to its *Pitta-Kapha Shamaka*, *Pandughna*, *Rasayana* (rejuvenative), *Deepana-Pachana* (digestive), *Raktavardhaka*, and *Anulomana* (laxative) properties which leads to the correction of metabolism, increase iron absorption, and improves blood formation. *Punarnava Mandura* contains the *Katu*, *Pittakapha Shamaka*, *Ruksha* (dry), *Shita* (cold), *Laghu* (light), and *Kashaya* (astringent). *Anulomana*, *Mutrala*<sup>[10]</sup> (diuretic), and *Punarnava* have been shown to have hepatoprotective and antioxidant properties. *Mandura Bhasma* has strong hepatoprotective, cytoprotective, and haematinic properties. *Triphala* is an Ayurvedic *rasayana* that has anti-oxidant and anti-anemic properties. *Rochana*, *Deepana*, and *Anulomana*, which are found in *Amalaki* (*Emblica officinalis* Gaertn.), are involved in the motility, absorption, and digestion of digestive contents in the gut. It directly affects *Rasavaha* and *Raktavaha Srotas* because it is *Hridya*, *Yakrututtejaka*, and *Shonita Sthapana*. It has been regarded as a powerful *Rasayana* that elevates the essence of each and every *Dhatu*s. Iron and vitamin C are abundant in *Amalaki*. One well-known bioavailability booster is *Trikatu*.

#### 4.3. Probable Mode of Action of *Kalmegha Capsule*

*Kalmegha* plant (*Andrographis peniculata*) is also known as “king of bitters.” It has anti-microbial, anti-protozoan, anti-oxidant, immune stimulant, anti-diabetic, anti-infective, hepato renal safe, liver modulator properties.<sup>[11]</sup> It has *Tikta Rasa* with *Katu Vipaka* and *Ushna Veerya*. It is *Kapha Pitta Doshahara* properties so it is used in *Yakrutroga*, *Krimiroga*, *Krimiroga*, *Kustha* and *Jwara*. Traditionally, it is used in common cold, diarrhoea, fever, jaundice, and health tonic for the liver. It is proven to possess anti-inflammatory, antibacterial, anti-thrombotic, hepato-protective properties. It also acts as antihepatotoxic, anti-cancerous and hypoglycemic, and hypotensive activity.

#### 4.4. Probable Mode of Action of *Medohara Guggulu*

*Medohara Guggulu* contains drugs like *Shunthi*, *Marich*, *Pippali*, *Chitraka*, *Haritaki*, *Vibhitaki*, *Amalaka*, *Musta*, *Vayavidanga*, and *Shudha Guggulu*, which is in the highest concentration in the combination. Approximate all the drugs having *Katu Rasa*, *Laghu Ruksha Guna*, *Katu Vipaka* with *Kapha Vata Shamaka* properties.<sup>[12]</sup> With these properties, it acts as *Deepana* (enlight digestive fire), *Pachak* (enhances digestion), *Meda-Kleda Shoshak* (scraps excessive *Meda* and *Kapha*), *Srotos Vishodhaka* (cleaning of micro channels), and *Lekhaniya* property. A crucial transcriptional regulator for the preservation of cholesterol and bile acid balance in bodily systems in guggulsterone, the bioactive component of *Guggulu*. Through the enterohepatic circulation, it transforms excess cholesterol into bile acid, which is the

body's main method of eliminating excess cholesterol and prevents from hepatic-steatosis.

#### 4.5. Probable Mode of Action of *Makoi Arka*

*Makoi* (black Night Shade), an herb is extensively used in traditional medicine to treat liver disorders and many more health problems. *Acharaya Charak* mentioned this drug under *Tikta Skanda*.<sup>[13]</sup> *Acharya Shusruta* has mentioned it under *Sursadi Gana*.<sup>[14]</sup> It contains *Tikta* (Bitter) *Rasa*, *Laghu* (light) *Snigdha* (slimy) *Guna*, *Anushan* (not too hot) *Virya*, *Katu* (pungent) *Vipaka*, *Tridoshaghana* (pacified all three doshas). It has properties to cure all liver disease.

### 5. CONCLUSION

Changes in the human habits and environmental variation is the major causative factor for all illness, including metabolic syndrome, which caused by poor nutrition and unhealthy lifestyle fatty liver is a progressive disease which may converts into end-stage liver disease such as liver cirrhosis, chronic liver disorder. No single or effective treatment for liver disease present in any medicine field which is cost-effective. Hence, we need some different modalities which are safe and cost-effective in nature. Some medications like *Arogyavardhini Vati*, *Punarnava Mandoor*, *Arka Makoi*, *Kalmegha* preparations are safe and effective in the case of *Yakrit Dalyudara* (NAFLD).

### 6. ACKNOWLEDGMENTS

Nil.

### 7. AUTHORS' CONTRIBUTIONS

All the authors contributed equally in design and execution of the article.

### 8. FUNDING

Nil.

### 9. ETHICAL APPROVALS

This study not required ethical approval as it is a case study.

### 10. CONFLICTS OF INTEREST

Nil.

### 11. DATA AVAILABILITY

This is an original manuscript and all data are available for only review purposes from principal investigators.

### 12. PUBLISHERS NOTE

This journal remains neutral with regard to jurisdictional claims in published institutional affiliation.

### REFERENCES

1. Mishra B. Bhavaprakasha with vidyotini hindi commentary by Pt. B.S Sharma. 7<sup>th</sup> ed., Ch. 33., Part 2. Varanasi: Chaukhamba Sanskrit Samsthana; 2000. p. 348-50.
2. Sitaram B. Bhavaprakasha samhita of Acharya bhavamishra, English commentary. Madhyama Khanda. Varanasi: Chowkhambha Orientalia; 2016.

3. Acharya YT, editor. Sushruta samhita of sushruta with the nibandhasangraha commentary of dalhanacharya. Varanasi: Chaukhamba Surbharti Prakashan; 2017.
4. Sastri Pradakara HS, editor. Ashtanga hridaya of vagbhata. Sutrasthana. Ch. 14., Ver. 21. Varanasi: Chaukhamba Sanskrit Sansthan; 2012. p. 226.
5. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-402.
6. Review Team, LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, Hamid SS, Isakov V, Lizarzabal M, Peñaranda MM, Ramos JF, Sarin S, Stimac D, Thomson AB, Umar M, Krabshuis J, LeMair A; World Gastroenterology Organisation. World gastroenterology organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014;48:467-73.
7. Acharya YT, Agnivesha. Charaka samhita, agnivesha treatise refined and annotated by charaka, reduced by dridhbala ayurveda Deepika commentary by chakrapanidatta. Varanasi: Chaukhamba Prakashana; 2011. p. 484, 738.
8. Trikamji VY, editor. Sushruta. Sushruta Samhita with nibandha sangraha vyakhyana by dalhanacharya and nyayachandrika khyapanji kavyakhyana by Gayadasa. 8<sup>th</sup> ed. Varanasi: Chaukhamba Krishnadas Academy; 2013. p. 458.
9. Padmaja D, Maheshwar T, Anuradha D, Koteswara Rao CV. Arogyavardhini vati - a boon for liver disorders from ayurveda (fatty liver). Ayushdhara. 2021;8:3418-25.
10. Santhosha DU, Manasa R, Vishwanath S, Shekhara Naik R, Mahesh MS. Hepatoprotective activity of *Boerhaavia diffusa* L. IP J Nutr Metab Health Sci. 2020;3:109-13.
11. Sabharwal S, Singh S, Anand N, Kaur S. An overview on Kalamegha (*Andrographis paniculata*). Asian Pac J Health Sci. 2021;8:57-65.
12. Singh S. A clinical study on hyperlipidemia with medohara guggulu and lekhanika mahakashaya. Int Ayurvedic Med J. 2016;4:606-612.
13. Tripathi B. Charak samhita of viman sthana, charak chandrika. Vol. 1, 8/143. Varanasi: Chaukhamba Subharti Prakashan; 2008. p. 782.
14. Shastri A. Sushruta samhita of sutra sthan, Ayurveda tatva sandipika. Part 1, 38/18. Varanasi: Chaukhamba Subharti Prakashan; 2010. p. 184.

#### How to cite this article:

Kumar D, Trivedi AB, Kumar SSM. A Case Report on Management of Non-alcoholic Grade 2 Fatty Liver WSR *Yakrit Vikara* through Ayurvedic Intervention. IRJAY. [online] 2025;8(5):33-38.

Available from: <https://irjay.com>

DOI link- <https://doi.org/10.48165/IRJAY.2025.80506>

**Table 1:** Therapeutic intervention

S. no.	Drug	Dose and frequency	Route of administration
1	<i>Arogyavardhini Vati</i>	500 mg twice a day	Oral
2	<i>Punarnava Mandoor</i>	500 mg twice a day	Oral
3	<i>Cap. Kaalmegha</i>	250 mg twice a day	Oral
4	<i>Medohara Guggulu</i>	500 mg twice a day	Oral
5	<i>Makoi Arka</i>	10 mL once a day (empty stomach)	Oral

**Table 2:** Timeline of events

Time line	Clinical presentation	Medication
Before February 2024	Heaviness in the abdomen, gaseous abdomen	Allopathic medication
February 19, 2024	Patient come to OPD of Kayachikitsa department of CBPACS with complaints of gaseous abdomen, weight gain, loss of appetite for 6 months. The patient came with an ultrasound report as mentioned in Figure 1. Then, patient was treated on OPD basis	<i>Arogyavardhini Vati, Medohara Gugglu, Makoi Arka</i>
February 26, 2024	Improvement present in gaseous abdomen	<i>Arogyavardhini Vati, Medohara Gugglu, Makoi Arka</i>
March 11, 2024	Mild improvement present in gaseous abdomen and loss of appetite	<i>Arogyavardhini Vati, Medohara Gugglu, Makoi Arka</i>
March 26, 2024	Mild improvement present in gaseous abdomen	<i>Arogyavardhini Vati, Medohara Gugglu, Makoi Arka</i>
April 08, 2024	No improvement present in loss of appetite and gaseous abdomen	<i>Arogyavardhini Vati, Medohara Gugglu, Makoi Arka, Punarnava Mandoor</i>
May 08, 2024	No improvement present in loss of appetite	<i>Arogyavardhini Vati, Medohara Gugglu, Makoi Arka, Capsule Kalmegha</i>
June 08, 2024	Improvement present	<i>Arogyavardhini Vati, Medohara Gugglu, Makoi Arka, Capsule Kalmegha</i>
June 22, 2024	Improvement present	Advised ultrasound whole abdomen
June 25, 2024	Improvement present	USG findings: - Liver is normal in size and show diffusely increased echogenicity, consistent with mild fatty infiltration.

OPD: Outpatient department



Table 3: Before and after treatment

Before treatment	After treatment
<div><p><b>DIAGNOSTICS REPORT</b></p><p>Patient Name: Mr. [REDACTED] Order Date: 03/02/2024 09:41 Age/Sex: 60 Years / Male Repeat Date: 03/02/2024 13:05 UHID: AHDW 200215 IP No: Ref. Doctor: Dr. Sahil Kapoor Facility: Aakash Healthcare</p><p><b>USG ABDOMEN + PELVIS</b></p><p><b>Study protocol:</b> - Ultrasound of abdomen and pelvis was done with curvilinear probe.</p><p><b>Clinical details:</b> - Routine checkup.</p><p><b>Hepatobiliary System</b> <b>LIVER:</b> Liver measures 12.9 cm in craniocaudal span and both lobes show grade II fatty changes with normal sized biliary and vascular channels. Both domes of the diaphragm move freely and subdiaphragmatic spaces are clear. No focal mass or intrahepatic biliary radical dilatation seen.</p><p><b>Gallbladder:</b> Gallbladder is well distended and shows normal wall thickness and an echo-free lumen. Common bile duct, Portal vein show normal course and caliber.</p><p><b>Pancreas:</b> The pancreas shows normal echogenicity, contour and size. Peri-pancreatic planes are clear.</p><p><b>Spleen:</b> The Spleen is normal in size and shows normal echo pattern. It measures 8.9 cm.</p><p><b>Kidneys and Excretory System:</b> The <b>right kidney</b> has a normal echo pattern in the cortex, medulla and excretory system and measures 9.4 x 4.5 cm. Cortico-medullary differentiation is maintained. No evidence of any calculus or hydronephrosis noted.</p><p>The <b>left kidney</b> has a normal echo pattern in the cortex, medulla and excretory system and measures 9.5 x 4.8 cm. Cortico-medullary differentiation is maintained. No evidence of any calculus or hydronephrosis noted.</p><p>The <b>urinary bladder</b> is well distended and shows normal contour and wall thickness. It shows an echo-free lumen.</p><p><b>Prostate:</b> Prostate is normal in size and weighs 20 grams.</p><p><b>Peritoneum and Retroperitoneum:</b> There is no free or loculated intraperitoneal fluid or obvious intra-abdominal lymphadenopathy.</p><p><b>IMPRESSION:</b> • Grade II fatty liver.</p><p>Please correlate clinically.</p><p>Dr. Jitendra Kaur, MBBS, DMRD (Radio Diagnosis) Senior Consultant Regio: 32136</p><p>AAKASH HEALTHCARE PRIVATE LIMITED CIN No. U85100DL1994PTC053336</p><p>24x7 Helpline 011- 433 888 88, 613 888 8</p></div>	<div><p><b>USG EXAMINATION : WHOLE ABDOMEN</b></p><p>Liver is normal in size and shows diffusely increased echogenicity, consistent with mild fatty infiltration. Intrahepatic biliary radicals are not dilated. No focal lesion seen.</p><p>Gall bladder show physiological distension and anechoic lumen. Wall thickness normal. No mass or calculus seen.</p><p>CBD is normal in diameter. No calculus seen.</p><p>Pancreas is normal in size and echotexture.</p><p>Spleen is normal in size and echotexture.</p><p>Both kidneys are normal in size and echotexture. Cortical and sinus echoes are normal. Cortico-medullary differentiation is preserved. No hydronephrosis or calculus is seen.</p><p>Right kidney : 9.1 x 4.7cm Left kidney : 9.1 x 5.1cm</p><p>Urinary Bladder appears normal. No mass or calculus seen.</p><p>Prostate is normal in size and echotexture.</p><p>No free fluid is seen in abdomen and pelvis.</p><p>Please correlate clinically.</p><p>Dr. Sonal Singhal</p><p>Facilities Available MRI, Multislice Spiral CT, Colour Doppler, Ultrasound, TRUS, TVS, Interventional, X.Rays</p></div>

Table 4: Pathya-Apathya diet regimen

Name	Pathya (wholesome diet)	Apathya (unwholesome diet)
Cereals	Shashtika, Yava, Gudhuma, Laja Manda	Rice flour, Tila, drugs having Ushna, Lavana, Amla, Vidhai Gunas
Pulses	Mugda	Masa
Fruits	Draksha, Apple, Pomegranate, Ripened Kiwi.	Orange, Lemon, Mango, Watermelon
Vegetable	Potato, Snake Guard, Beans, Shigru, Brinjal, Potato, Jeevanti, Raddish	Chilly, Bitter Guard, Pickle, Pumpkin, All Leafy Vegetables (Saka)
Milk products	Ghee, Milk, Takra	Curd
Non veg	Mamsa Rasa with Dashmoola	All fishes
Others	Gomootra, Asava, Arsihta.	Sura, Madya, water <1,000 mL, Salt